An autoimmune condition called alopecia areata is another relatively common cause of hair loss, affecting about 2% of people at some point during their lives (Stough 2005
Results from the first Phase III trial in obesity and overweight investigating the GIPR/GLP-1R co-agonist tirzepatide, which is currently approved for the treatment of type 2 diabetes and has resulted in marked body-weight reductions in type 2 diabetes [5, 43,44,45,46], were published in 2022 [28]
Over 64% of people without diabetes and nearly 47% of those with diabetes stopped GLP-1 therapy within a year
GLP-3(Reta) Phase 2 data showed approximately 17.5% at 24 weeks, with Phase 3 ongoing
High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice
California Trim Clinic works with licensed pharmacy partners and does not source research-grade, gray-market, or black-market peptide products